Half-year report · HY
2796.TEDINET S100XF31
Period2025-06-01 → 2025-11-30
Filed2026-01-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33.6bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥63.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥30.5bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | ¥399m | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥100m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥328m | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥136m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥29m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥368m | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥34m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥111m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥367m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥113m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥106m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | −¥121m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥30.0bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥31.9bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥30.5bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥23.1bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥25.0bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.8bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥6.9bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.9bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.6bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.5bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.1bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥220m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥200m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥449m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥537m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.7bn | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥939m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥9.75 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-32.48 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.09 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥9.37 | 2025-06-01 → 2025-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.1% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.9% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.6% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-06-01 → 2025-11-30 | ¥459m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-06-01 → 2025-11-30 | ¥459m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-06-01 → 2025-11-30 | −¥92m |
| Reconciling Itemsreconciling | segment profit | 2025-06-01 → 2025-11-30 | −¥169m |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥4.1bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥4.1bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2025-06-01 → 2025-11-30 | −¥21m |
| Custody Of Medical Documentsreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥322m |
| Custody Of Medical Documentsreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥322m |
| Custody Of Medical Documentsreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥43m |
| Dispensing Pharmacyreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥28.5bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥28.5bn |
| Dispensing Pharmacyreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥589m |
| Medical Mallreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥257m |
| Medical Mallreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥257m |
| Medical Mallreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥48m |
| —segment total | revenue | 2025-06-01 → 2025-11-30 | ¥33.1bn |
| —segment total | revenue external | 2025-06-01 → 2025-11-30 | ¥33.1bn |
| —segment total | segment profit | 2025-06-01 → 2025-11-30 | ¥660m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-06-01 → 2025-11-30 | ¥33.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-06-01 → 2025-11-30 | ¥33.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-06-01 → 2025-11-30 | ¥568m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-06-01 → 2024-11-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-06-01 → 2024-11-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-06-01 → 2024-11-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥175m |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.5bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.5bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥1m |
| Custody Of Medical Documentsreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥311m |
| Custody Of Medical Documentsreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥311m |
| Custody Of Medical Documentsreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥22m |
| Dispensing Pharmacyreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥24.9bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥24.9bn |
| Dispensing Pharmacyreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥202m |
| Medical Mallreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥256m |
| Medical Mallreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥256m |
| Medical Mallreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥58m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥30.0bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥30.0bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥282m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥30.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥30.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥276m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 557
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)太陽有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)田 尻 慶 太 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)古 市 岳 久 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1InterimDuration | 30544000000 | JPY |
| Net sales (5-year summary) | InterimDuration | 33602000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 63508000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1InterimDuration | 29000000 | JPY |
| Ordinary income loss (5-year summary) | InterimDuration | 328000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 136000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1InterimDuration | -113000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | InterimDuration | 111000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | -367000000 | JPY |
| Comprehensive income (5-year summary) | Prior1InterimDuration | -125000000 | JPY |
| Comprehensive income (5-year summary) | InterimDuration | 100000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | -370000000 | JPY |
| Net assets (5-year summary) | Prior1InterimInstant | 7163000000 | JPY |
| Net assets (5-year summary) | InterimInstant | 6834000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 6918000000 | JPY |
| Total assets (5-year summary) | Prior1InterimInstant | 30457000000 | JPY |
| Total assets (5-year summary) | InterimInstant | 29956000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 31924000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1InterimDuration | -10.09 | |
| Basic earnings loss per share (5-year summary) | InterimDuration | 9.75 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | -32.48 | |
| Diluted earnings per share (5-year summary) | Prior1InterimDuration | － | |
| Diluted earnings per share (5-year summary) | InterimDuration | 9.37 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1InterimInstant | 0.226 | |
| Equity to asset ratio (5-year summary) | InterimInstant | 0.221 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.209 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1InterimDuration | -200000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | InterimDuration | -220000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 1311000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1InterimDuration | -537000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | InterimDuration | -449000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -4462000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1InterimDuration | 1138000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | InterimDuration | -1666000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 939000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1InterimInstant | 7504000000 | JPY |
| Cash and cash equivalents (5-year summary) | InterimInstant | 2555000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 4891000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 12060381 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 12060381 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 12060381 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 12060381 | |
| Number of shares held | InterimInstant_No1MajorShareholdersMember | 3015000 | |
| Shareholding ratio | InterimInstant_No1MajorShareholdersMember | 0.262 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |